34 related articles for article (PubMed ID: 34089074)
21. Fat-free muscle area measured by magnetic resonance imaging predicts overall survival of patients undergoing radioembolization of colorectal cancer liver metastases.
Faron A; Pieper CC; Schmeel FC; Sprinkart AM; Kuetting DLR; Fimmers R; Trebicka J; Schild HH; Meyer C; Thomas D; Luetkens JA
Eur Radiol; 2019 Sep; 29(9):4709-4717. PubMed ID: 30689036
[TBL] [Abstract][Full Text] [Related]
22. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Zu Q; Schenning RC; Jahangiri Y; Tomozawa Y; Kolbeck KJ; Kaufman JA; Al-Hakim R; Naugler WE; Nabavizadeh N; Kardosh A; Billingsley KG; Mayo SC; Orloff SL; Enestvedt KK; Maynard E; Ahn J; Lhewa D; Farsad K
Cardiovasc Intervent Radiol; 2020 May; 43(5):721-731. PubMed ID: 32140840
[TBL] [Abstract][Full Text] [Related]
23. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.
Kwok PC; Leung KC; Cheung MT; Lam TW; Szeto LT; Chou SQ; Chia NH; Tong CM; Yuen PK; Cheung CH; Law CK
J Gastroenterol Hepatol; 2014 Nov; 29(11):1897-904. PubMed ID: 24734957
[TBL] [Abstract][Full Text] [Related]
24. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
25. Magnetic resonance parametric mapping of the spleen for non-invasive assessment of portal hypertension.
Mesropyan N; Isaak A; Faron A; Praktiknjo M; Jansen C; Kuetting D; Meyer C; Pieper CC; Sprinkart AM; Chang J; Maedler B; Thomas D; Kupczyk P; Attenberger U; Luetkens JA
Eur Radiol; 2021 Jan; 31(1):85-93. PubMed ID: 32749584
[TBL] [Abstract][Full Text] [Related]
26. MRI-Derived Sarcopenia Associated with Increased Mortality Following Yttrium-90 Radioembolization of Hepatocellular Carcinoma.
Guichet PL; Taslakian B; Zhan C; Aaltonen E; Farquharson S; Hickey R; Horn CJ; Gross JS
Cardiovasc Intervent Radiol; 2021 Oct; 44(10):1561-1569. PubMed ID: 34089074
[TBL] [Abstract][Full Text] [Related]
27. Imaging of Hepatocellular Carcinoma Response After
Semaan S; Makkar J; Lewis S; Chatterji M; Kim E; Taouli B
AJR Am J Roentgenol; 2017 Nov; 209(5):W263-W276. PubMed ID: 29072955
[TBL] [Abstract][Full Text] [Related]
28. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
29. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.
Jia Z; Jiang G; Tian F; Zhu C; Qin X
Saudi J Gastroenterol; 2016; 22(5):353-359. PubMed ID: 27748320
[TBL] [Abstract][Full Text] [Related]
30. Yttrium-90 Radioembolization for Hepatocellular Carcinoma.
Hickey RM; Lewandowski RJ; Salem R
Semin Nucl Med; 2016 Mar; 46(2):105-8. PubMed ID: 26897714
[TBL] [Abstract][Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
